Taysha Gene Therapies Inc Ordinary Shares TSHA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $6.34
- Day Range
- $5.32–6.29
- 52-Week Range
- $2.34–7.30
- Bid/Ask
- $5.38 / $5.51
- Shares Outstanding
- 319.86M
- Market Cap
- $1.55B
- Volume/Avg
- 1,094 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 247.76
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 99
- Website
- https://www.tayshagtx.com
Valuation
|
Metric
|
TSHA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.29 |
Price/Sales | 247.76 |
Price/Cash Flow | — |
Price/Earnings
TSHA
Financial Strength
|
Metric
|
TSHA
|
|---|---|
Quick Ratio | 13.76 |
Current Ratio | 14.04 |
Interest Coverage | −2,647.30 |
Quick Ratio
TSHA
Profitability
|
Metric
|
TSHA
|
|---|---|
Return on Assets (Normalized) | −39.47% |
Return on Equity (Normalized) | −57.57% |
Return on Invested Capital (Normalized) | −47.11% |
Return on Assets
TSHA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|hghg^p | LOCK|x<$L | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$YwPLSg | LOCK|n#C#% | $70B | |||
| argenx SE ADR
ARGX
| LOCK|kG@BKB | LOCK|^# | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|vm&q$g@ | LOCK|nk^$k | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^&$<%% | LOCK|G@< | $36B | |||
| Moderna Inc
MRNA
| LOCK|SnW!!dQ | LOCK|&Q% | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|T#cMFWyM | LOCK|%D<Ql | $25B | |||
| Incyte Corp
INCY
| LOCK|QLGp&c | LOCK|Ntx | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?>?ppB | LOCK|B<? | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|?QH$&z | LOCK|?w | $16B |
United States